novartis ag fda warns drug firm over certain promotions novartis ag was warned by the food and drug administration that certain promotional material for the swiss drug companys alzheimers drug exelon was "misleading" and overstated the drugs effectiveness in an aug warning letter sent to novartis the fda said a so called professional file card for exelon also makes unsubstantiated superiority claims and includes misleading risk presentations the fda ordered novartis to stop distributing the professional file card and any other similar promotional material novartis said it is reviewing the fdas letter and said it would "take the necessary steps to ensure that all of our promotional materials are in full compliance with fda regulations " 
